Anesthesia
Pharmacology: Gastrointestinal Pharmacology Practice Questions
Choose the correct answer for each question.
Oral sulfasalazine clinical efficacy:
- Effective corrective ulcerative colitis considered To be of mild or moderate severity.
- Sulfasalazine is less likely to be effective in treating severe colitis.
- Both
- Neither
Relapses of ulcerative colitis may be prevented by sulfasalazine administration.
- True
- False
Superior agent with respect to therapeutic efficacy in treating active proctitis and distal ulcerative colitis.
- Topical mesalamine (suspension enema or wax suppository)
- Topical hydrocortisone
- Both equally effective
Concerning 5-acetylsalicylic acid (5-ASA) pharmacokinetics:
- About a third of orally administered sulfasalazine is absorbed in the small intestine.
- Sulfasalazine reaching the: will be activated (mesalamine) by bacterial enzymes.
- Both
- Neither
Concerning sulfasalazine adverse effects:
- Side effects are likely related to the "sulfa" moiety
- Dose-related side effects of social cells seen can be limited by either decreasing the dose or administering the medication with food.
- Both
- Neither
Sulfasalazine decreases intestinal folate absorption and accordingly is often administered with folate supplementation.
- True
- False
Diarrhea is most likely associated with this agent
- Olsalazine
- Mesalamine
- Sulfasalazine
Lialda (methylmelamine) is a delayed-release tablet formulation.
- True
- False
Formulation least likely to be released in the small intestine:
- Sulfasalazine
- 5-ASA pH-dependent release (Lialda)
- 5-ASA delayed-release capsule (Pentasa)
Hypersensitivity reaction(s) to sulfapyridine (or very occasionally, 5-ASA):
- Exfoliative dermatitis
- Fever
- Pancreatitis
- Hepatitis
- A & B
- A & C
- A, B & C
- A, B, C & D (all of the responses)